{
  "Disease": [
    {"role": "user", "content": "Please identify the \"Disease\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Disease\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: RESULTS : Verapamil significantly increased PRL levels in healthy controls ( N . 8 , PRL : 183 % ) , macroprolactinoma ( N . 8 , PRL : 7 % ) , microprolactinoma ( N . 19 , PRL : 21 % ) , macroprolactinemia ( N . 23 , PRL : 126 % ) , but not in pseudoprolactinoma ( N . 8 , PRL : 0 . 8 % ) , and risperidone - induced hyperprolactinemia ( N . 7 , PRL : 3 % ) .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| healthy controls |\n| macroprolactinoma |\n| microprolactinoma |\n| macroprolactinemia |\n| pseudoprolactinoma |\n| risperidone-induced hyperprolactinemia |"},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Disease\" and present the valid entities as a Markdown table with one column \"Disease\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| macroprolactinoma |\n| microprolactinoma |\n| macroprolactinemia |\n| pseudoprolactinoma |\n\nNote: \"healthy controls\" is not a disease, it refers to a group of individuals without the disease under investigation.\n\n\"risperidone-induced hyperprolactinemia\" is a valid disease entity, it refers to an increase in prolactin levels caused by the use of the medication risperidone."}
  ],
  "Chemical": [
    {"role": "user", "content": "Please identify the \"Chemical\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Chemical\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: RESULTS : Verapamil significantly increased PRL levels in healthy controls ( N . 8 , PRL : 183 % ) , macroprolactinoma ( N . 8 , PRL : 7 % ) , microprolactinoma ( N . 19 , PRL : 21 % ) , macroprolactinemia ( N . 23 , PRL : 126 % ) , but not in pseudoprolactinoma ( N . 8 , PRL : 0 . 8 % ) , and risperidone - induced hyperprolactinemia ( N . 7 , PRL : 3 % ) .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| Verapamil |\n| Prolactin (PRL) |\n| Macroprolactinoma |\n| Microprolactinoma |\n| Macroprolactinemia |\n| Risperidone |"},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Chemical\" and present the valid entities as a Markdown table with one column \"Chemical\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| Verapamil |\n| Prolactin (PRL) |\n\nThe other entities in the paragraph do not refer to chemicals, but rather to medical conditions or abnormalities associated with increased levels of Prolactin (PRL)."}
  ]
}